FDA Oncology Announcements

Bcr-Abl inhibitor × Lymphoid × Clear all

3 Announcements

FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Drug: Iclusig (ponatinib) · Bcr-Abl inhibitor
Conditions: LymphoidOther hematologic neoplasm

FDA Approves Ponatinib

Drug: Iclusig tablets (ponatinib) · Bcr-Abl inhibitor
Conditions: LymphoidMyeloid

FDA Approves Dasatinib

Drug: Sprycel (dasatinib) · Bcr-Abl inhibitor
Conditions: LymphoidMyeloid